PDC/PDCX-based and pathological analyses of RCC uncovered that NRN1 and its co-expressing molecule CXCR4 are positively associated with RCC patient prognosis and their silencing substantially suppresses PDC viability and PDCX tumor growth. Here, NRN1 is linked to neoplasm.